Immunomodulatory Thermal Ablation in Hepatocellular Carcinoma

Thermal ablation has emerged as a pivotal treatment for early‐stage hepatocellular carcinoma, offering a minimally invasive means of tumour destruction. Modalities such as radiofrequency ablation, microwave ablation and cryoablation not only achieve local coagulative necrosis but also liberate tumour antigens and danger signals, thereby engaging both innate and adaptive immune mechanisms. However, incomplete ablation can foster an immunosuppressive tumour microenvironment characterised by myeloid cell infiltration and regulatory cytokine production, which may undermine long‐term control. To convert local cytoreduction into systemic anticancer immunity, combination strategies now incorporate checkpoint inhibitors, dendritic cell activators and metabolic or post-translational modifiers. Recent mechanistic insights into antigen presentation, myeloid-derived suppressor cell dynamics and T-cell priming have revealed actionable targets, with the ultimate aim of turning ablative platforms into in situ cancer vaccines and improving survival in a disease of rising global burden.

Research from Nature Portfolio

Recent studies have shown that incomplete radiofrequency ablation can paradoxically accelerate tumour progression and limit the efficacy of PD-1 blockade by sustaining local inflammation dominated by CCR2-dependent monocyte and macrophage infiltration. Crosstalk between tumour cells and tumour-associated macrophages amplifies CCL2 production, reinforcing immunosuppressive circuits. Pharmacological inhibition of CCR2 or genetic ablation of CCL2 restores T-cell activity and enhances checkpoint inhibitor responses in preclinical models of liver metastasis, offering a template for improving ablation-based regimens.

Immunomodulatory Thermal Ablation in Hepatocellular Carcinoma publication trend

The graph below shows the total number of articles in immunomodulatory thermal ablation in hepatocellular carcinoma across all publications each year (not limited to Nature Index journals).

Technical terms

Radiofrequency ablation (RFA): A locoregional therapy using high-frequency electrical currents to induce thermal coagulation and necrosis of tumour tissue.

Tumour microenvironment (TME): The complex milieu of cancer cells, stromal elements, immune cells and signalling molecules surrounding a tumour.

Dendritic cell (DC): An antigen-presenting leukocyte critical for priming T-cell responses against tumour antigens.

Immune checkpoint (PD-1): A regulatory receptor on T cells that modulates immune activity and can be blocked to enhance antitumour immunity.

SUMOylation: A post-translational modification where a small ubiquitin-like modifier protein is attached to target proteins, influencing cellular stress responses.

Nanocomposite hydrogel: A three-dimensional polymeric network incorporating nanoparticles to enable sustained local delivery of therapeutic agents.

References

1. Targeting SLC7A11/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti‐tumor immune response. iMeta (2024).
2. Targeting SUMOylation with an injectable nanocomposite hydrogel to optimize radiofrequency ablation therapy for hepatocellular carcinoma. Journal of Nanobiotechnology (2024).
3. Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation. Journal of Experimental & Clinical Cancer Research (2023).
4. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nature Communications (2019).